PortfoliosLab logoPortfoliosLab logo
TEVA vs. ATEYY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

TEVA vs. ATEYY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Teva Pharmaceutical Industries Limited (TEVA) and Advantest Corp DRC (ATEYY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, TEVA achieves a 10.96% return, which is significantly lower than ATEYY's 38.53% return. Over the past 10 years, TEVA has underperformed ATEYY with an annualized return of -3.83%, while ATEYY has yielded a comparatively higher 52.65% annualized return.


TEVA

1D
0.20%
1M
-4.47%
YTD
10.96%
6M
16.25%
1Y
95.54%
3Y*
66.30%
5Y*
25.53%
10Y*
-3.83%

ATEYY

1D
4.13%
1M
-3.29%
YTD
38.53%
6M
38.14%
1Y
200.38%
3Y*
71.51%
5Y*
50.50%
10Y*
52.65%
*Multi-year figures are annualized to reflect compound growth (CAGR)

TEVA vs. ATEYY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
TEVA
Teva Pharmaceutical Industries Limited
10.96%41.61%111.11%14.47%13.86%-16.99%-1.53%-36.45%-18.63%-46.18%
ATEYY
Advantest Corp DRC
38.53%122.70%68.99%111.43%-33.43%27.37%30.96%176.84%12.51%12.66%

Correlation

The correlation between TEVA and ATEYY is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.24

Correlation (3Y)
Calculated over the trailing 3-year period

0.21

Correlation (5Y)
Calculated over the trailing 5-year period

0.24

Correlation (10Y)
Calculated over the trailing 10-year period

0.18

Correlation (All Time)
Calculated using the full available price history since Jan 4, 2016

0.17

Fundamentals

Market Cap

TEVA:

$40.83B

ATEYY:

$127.67B

EPS

TEVA:

$1.34

ATEYY:

¥520.21

PE Ratio

TEVA:

25.89

ATEYY:

53.89

PEG Ratio

TEVA:

0.20

ATEYY:

0.69

PS Ratio

TEVA:

2.33

ATEYY:

17.92

PB Ratio

TEVA:

4.96

ATEYY:

25.59

Total Revenue (TTM)

TEVA:

$17.35B

ATEYY:

¥1.14T

Gross Profit (TTM)

TEVA:

$9.03B

ATEYY:

¥736.09B

EBITDA (TTM)

TEVA:

$3.05B

ATEYY:

¥533.69B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

TEVA vs. ATEYY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TEVA
TEVA Risk / Return Rank: 9393
Overall Rank
TEVA Sharpe Ratio Rank: 9393
Sharpe Ratio Rank
TEVA Sortino Ratio Rank: 9494
Sortino Ratio Rank
TEVA Omega Ratio Rank: 9393
Omega Ratio Rank
TEVA Calmar Ratio Rank: 9191
Calmar Ratio Rank
TEVA Martin Ratio Rank: 9292
Martin Ratio Rank

ATEYY
ATEYY Risk / Return Rank: 9393
Overall Rank
ATEYY Sharpe Ratio Rank: 9595
Sharpe Ratio Rank
ATEYY Sortino Ratio Rank: 9191
Sortino Ratio Rank
ATEYY Omega Ratio Rank: 8989
Omega Ratio Rank
ATEYY Calmar Ratio Rank: 9494
Calmar Ratio Rank
ATEYY Martin Ratio Rank: 9494
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TEVA vs. ATEYY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Teva Pharmaceutical Industries Limited (TEVA) and Advantest Corp DRC (ATEYY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


TEVAATEYYDifference
Sharpe ratioReturn per unit of total volatility

-0.40

Sortino ratioReturn per unit of downside risk

+0.50

Omega ratioGain probability vs. loss probability

1.47

1.39

+0.08

Calmar ratioReturn relative to maximum drawdown

4.41

6.07

-1.66

Martin ratioReturn relative to average drawdown

12.66

16.34

-3.69

TEVA vs. ATEYY - Sharpe Ratio Comparison

The current TEVA Sharpe Ratio is 2.46, which is comparable to the ATEYY Sharpe Ratio of 2.87. The chart below compares the historical Sharpe Ratios of TEVA and ATEYY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

TEVA vs. ATEYY - Drawdown Comparison

The maximum TEVA drawdown since its inception was -90.89%, which is greater than ATEYY's maximum drawdown of -56.48%. Use the drawdown chart below to compare losses from any high point for TEVA and ATEYY.


Loading charts...

Drawdown Indicators


TEVAATEYYDifference

Max Drawdown

Largest peak-to-trough decline

-90.89%

-56.48%

-34.41%

Max Drawdown (1Y)

Largest decline over 1 year

-21.79%

-33.24%

+11.45%

Max Drawdown (3Y)

Largest decline over 3 years

-43.70%

-44.70%

+1.00%

Max Drawdown (5Y)

Largest decline over 5 years

-43.70%

-56.48%

+12.78%

Max Drawdown (10Y)

Largest decline over 10 years

-88.41%

-56.48%

-31.93%

Current Drawdown

Current decline from peak

-48.81%

-11.76%

-37.05%

Average Drawdown

Average peak-to-trough decline

-32.00%

-14.23%

-17.77%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.72%

12.32%

-4.60%

Volatility

TEVA vs. ATEYY - Volatility Comparison

The current volatility for Teva Pharmaceutical Industries Limited (TEVA) is 10.61%, while Advantest Corp DRC (ATEYY) has a volatility of 27.35%. This indicates that TEVA experiences smaller price fluctuations and is considered to be less risky than ATEYY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


TEVAATEYYDifference

Volatility (1M)

Calculated over the trailing 1-month period

10.61%

27.35%

-16.74%

Volatility (6M)

Calculated over the trailing 6-month period

23.72%

55.16%

-31.44%

Volatility (1Y)

Calculated over the trailing 1-year period

39.04%

70.37%

-31.33%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

42.82%

53.29%

-10.47%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

47.35%

48.58%

-1.23%

Dividends

TEVA vs. ATEYY - Dividend Comparison

Neither TEVA nor ATEYY has paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
ATEYY
Advantest Corp DRC
0.00%0.11%0.22%0.00%0.00%0.00%0.00%0.00%0.00%1.18%1.24%0.00%
TEVA
Teva Pharmaceutical Industries Limited
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%3.88%3.19%1.77%

Financials

TEVA vs. ATEYY - Financials Comparison

This section allows you to compare key financial metrics between Teva Pharmaceutical Industries Limited and Advantest Corp DRC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00B100.00B150.00B200.00B250.00B300.00B350.00B20222023202420252026
3.98B
334.10B
(TEVA) Total Revenue
(ATEYY) Total Revenue
Please note, different currencies. TEVA values in USD, ATEYY values in JPY

TEVA vs. ATEYY - Profitability Comparison

The chart below illustrates the profitability comparison between Teva Pharmaceutical Industries Limited and Advantest Corp DRC over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

45.0%50.0%55.0%60.0%65.0%20222023202420252026
49.5%
67.4%
Portfolio components
TEVA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a gross profit of 1.97B and revenue of 3.98B. Therefore, the gross margin over that period was 49.5%.

ATEYY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Advantest Corp DRC reported a gross profit of 225.18B and revenue of 334.10B. Therefore, the gross margin over that period was 67.4%.

TEVA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported an operating income of 652.00M and revenue of 3.98B, resulting in an operating margin of 16.4%.

ATEYY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Advantest Corp DRC reported an operating income of 156.38B and revenue of 334.10B, resulting in an operating margin of 46.8%.

TEVA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a net income of 369.00M and revenue of 3.98B, resulting in a net margin of 9.3%.

ATEYY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Advantest Corp DRC reported a net income of 129.16B and revenue of 334.10B, resulting in a net margin of 38.7%.


Frequently Asked Questions


TEVA and ATEYY have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ATEYY has higher volatility (27.35%) compared to TEVA (10.61%). In terms of maximum drawdown, TEVA dropped -90.89% vs ATEYY's -56.48%.

ATEYY currently has the higher Sharpe Ratio (2.87 vs 2.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for TEVA and ATEYY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer